<DOC>
	<DOCNO>NCT00032786</DOCNO>
	<brief_summary>The purpose study determine safety efficacy natalizumab individual diagnose moderate severely active Crohn 's disease . It think natalizumab may stop movement certain cell , know white blood cell , bowel tissue . These cell think cause damage bowel lead symptom Crohn 's disease .</brief_summary>
	<brief_title>Safety Efficacy Natalizumab Treatment Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Male female patient least 18 year age least sixmonth history Crohn 's disease currently experience moderate severely active Crohn 's disease . Women must breastfeed pregnant , must become pregnant study . Patient enrollment require previous participation study AN100226CD301 ( please refer clinical trial list CD301 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>